Aevi Genomic Medicine (NASDAQ:GNMX) and Crispr Therapeutics (NASDAQ:CRSP) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their analyst recommendations, dividends, risk, valuation, earnings, profitability and institutional ownership.
Volatility and Risk
Aevi Genomic Medicine has a beta of 0.32, meaning that its share price is 68% less volatile than the S&P 500. Comparatively, Crispr Therapeutics has a beta of 3.12, meaning that its share price is 212% more volatile than the S&P 500.
This is a breakdown of current ratings for Aevi Genomic Medicine and Crispr Therapeutics, as provided by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|Aevi Genomic Medicine||0||1||0||0||2.00|
Crispr Therapeutics has a consensus target price of $46.70, indicating a potential upside of 25.72%. Given Crispr Therapeutics’ stronger consensus rating and higher possible upside, analysts plainly believe Crispr Therapeutics is more favorable than Aevi Genomic Medicine.
This table compares Aevi Genomic Medicine and Crispr Therapeutics’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|Aevi Genomic Medicine||N/A||-206.46%||-153.74%|
Insider and Institutional Ownership
19.2% of Aevi Genomic Medicine shares are held by institutional investors. Comparatively, 43.5% of Crispr Therapeutics shares are held by institutional investors. 11.7% of Aevi Genomic Medicine shares are held by insiders. Comparatively, 37.7% of Crispr Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.
Valuation & Earnings
This table compares Aevi Genomic Medicine and Crispr Therapeutics’ gross revenue, earnings per share (EPS) and valuation.
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|Aevi Genomic Medicine||N/A||N/A||-$30.77 million||($0.83)||-0.25|
|Crispr Therapeutics||$3.12 million||622.50||-$164.98 million||($3.44)||-10.80|
Aevi Genomic Medicine has higher earnings, but lower revenue than Crispr Therapeutics. Crispr Therapeutics is trading at a lower price-to-earnings ratio than Aevi Genomic Medicine, indicating that it is currently the more affordable of the two stocks.
Crispr Therapeutics beats Aevi Genomic Medicine on 9 of the 12 factors compared between the two stocks.
Aevi Genomic Medicine Company Profile
Aevi Genomic Medicine, Inc., a clinical stage biopharmaceutical company, researches and develops novel therapies for pediatric onset and life-altering diseases in the United States. The company's lead product candidates include AEVI-001, a glutamatergic neuromodulator, which has completed Phase II/III SAGA trial for the treatment of a genetically-defined subset of adolescent attention deficit hyperactivity disorder patients who have genetic mutations that disrupt the mGluR network resulting in glutamate imbalance; and AEVI-002, an anti-LIGHT monoclonal antibody that is in Phase Ib clinical trial for use in severe pediatric onset Crohn's disease. The company also develops AEVI-005, which is in preclinical stage for the treatment of pediatric rare diseases. It has a strategic collaboration with Kyowa Hakko Kirin Co., Ltd. for an early stage monoclonal antibody program in an ultra-orphan pediatric indication. The company was formerly known as Medgenics, Inc. and changed its name to Aevi Genomic Medicine, Inc. in December 2016. Aevi Genomic Medicine, Inc. was founded in 2000 and is based in Wayne, Pennsylvania.
Crispr Therapeutics Company Profile
CRISPR Therapeutics AG, a gene editing company, focuses on developing transformative gene-based medicines for the treatment of serious human diseases using its regularly interspaced short palindromic repeats associated protein-9 (CRISPR/Cas9) gene-editing platform in Switzerland. Its lead product candidate is CTX001, which targets sickle cell disease and beta-thalassemia with an ex vivo approach whereby cells are harvested from a patient, treated with a CRISPR/Cas9-based therapeutic and reintroduced into the patient. The company is also developing CTX101, a donor-derived gene-edited allogeneic CAR-T therapy targeting CD19-positive malignancies. In addition, it is developing earlier stage allogeneic CAR-T programs targeting B-Cell maturation antigen and CD70; hemoglobinopathies to treat other diseases, including Hurler Syndrome and severe combined immunodeficiency disease; programs that are in preclinical development for indications, including glycogen storage disease Ia and hemophilia; and programs targeting diseases of organ systems outside the liver, such as Duchenne muscular dystrophy and cystic fibrosis. It has a collaboration agreement with Vertex Pharmaceuticals, Incorporated Vertex Pharmaceuticals (Europe) Limited to develop, manufacture, commercialize, sell, and use therapeutics. The company also has research collaboration agreements with Neon Therapeutics for developing neoantigen-based therapeutic vaccines and T cell therapies; Massachusetts General Hospital Cancer Center to develop T cell therapies for cancer; and with the ViaCyte, Inc. for designing allogeneic cell therapies derived from gene edited human stem cells for use in the treatment of diabetes type 1, diabetes type 2, and insulin dependent diabetes. CRISPR Therapeutics AG is headquartered in Zug, Switzerland.
Receive News & Ratings for Aevi Genomic Medicine Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aevi Genomic Medicine and related companies with MarketBeat.com's FREE daily email newsletter.